PARP inhibition — not all gene mutations are created equal

Research output: Contribution to journalArticlepeer-review

13 Scopus citations


Preliminary results from TRITON2 demonstrate efficacy of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in ~50% of patients with metastatic castration-resistant prostate cancer and inactivation of BRCA1/BRCA2. However, those with ATM and CDK12 mutations do not seem to benefit. An improved homologous recombination deficiency test must be developed and alternative treatments defined for these subsets of patients.

Original languageEnglish (US)
Pages (from-to)4-6
Number of pages3
JournalNature Reviews Urology
Issue number1
StatePublished - Jan 1 2019
Externally publishedYes

Bibliographical note

Funding Information:
This work was partially supported by NIH Cancer Center Support Grant P30 CA006973, the Department of Defense (DOD) grant W81XWH-16-PCRP-CCRSA, NIH grant R01 CA185297, and US Department of Defense Prostate Cancer Research Program grant W81XWH-15-2-0050, and the Patrick C. Walsh Research Fund.

Publisher Copyright:
© 2018, Springer Nature Limited.


Dive into the research topics of 'PARP inhibition — not all gene mutations are created equal'. Together they form a unique fingerprint.

Cite this